N-(4,6-dichloro-1-methyl-1H-imidazo[4,5-c]pyridin-7-yl)-N'-methylbenzamidine | 1134816-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-(4,6-dichloro-1-methyl-1H-imidazo[4,5-c]pyridin-7-yl)-N'-methylbenzamidine
• 英文别名: N-(4,6-Dichloro-1-methyl-1H-imidazo[4,5-c]pyridin-7-yl)-Na(2)-methylbenzenecarboximidamide；N-(4,6-dichloro-1-methylimidazo[4,5-c]pyridin-7-yl)-N'-methylbenzenecarboximidamide
• CAS: 1134816-40-2
• 化学式: C₁₅H₁₃Cl₂N₅
• 分子量: 334.208
• InChiKey: USCQQAXJFOANMJ-UHFFFAOYSA-N

反应信息

• 作为反应物：
  描述：

  N-(4,6-dichloro-1-methyl-1H-imidazo[4,5-c]pyridin-7-yl)-N'-methylbenzamidine 在 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以67%的产率得到7-chloro-1,4-dimethyl-2-phenyl-4H-imidazo[4,5-d]imidazo[5,4-b]-pyridine
  参考文献：
  名称：

  Novel Tricyclic Inhibitors of IκB Kinase

  摘要：

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

  DOI：

  10.1021/jm8015816
• 作为产物：
  描述：

  、 盐酸甲胺 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以0.8 g的产率得到N-(4,6-dichloro-1-methyl-1H-imidazo[4,5-c]pyridin-7-yl)-N'-methylbenzamidine
  参考文献：
  名称：

  Novel Tricyclic Inhibitors of IκB Kinase

  摘要：

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

  DOI：

  10.1021/jm8015816